/

EDSA

Edesa Biotech, Inc.Closed

2.85−0.10 −3.23%USD

NasdaqCM · as of Oct 13, 16:00 ET · 15m delay

Open

2.89

Prev close

2.94

Day range

2.823.09

52-week range

0.720020.32

Volume

59.74K0.96×

Mkt cap

38.44M

P/E ttm

—

Fwd P/E

—

EPS ttm

-1.65

Div yield

0.00%

Earnings

—

From 52w high

−86.00%

Price Chart

Yahoo Finance · delayed

EDSAOct 13, 2026O 2.89H 3.09L 2.82C 2.85−0.09 (−3.06%)Vol 59.70K

SMA 504.47
SMA 2005.58

1Y change +12.20% since Oct 13, 2025 close539 bars loadedTimes in America/New_YorkDraw from the left toolbar · click a drawing to edit · right-click for alerts and export

EDSA Edesa Biotech, Inc. · Last Guard Finance

DES

Key Statistics

Yahoo Finance

Performance

1 week: −23.39%
1 month: −32.62%
3 months: −57.72%
6 months: −45.40%
Year to date: +100.70%
1 year: +12.20%

Valuation & ownership

Market cap: 38.44M
Enterprise value: 25.51M
P/E (ttm): —
Forward P/E: —
PEG ratio: —
Price / book: 69.39
Price / sales (ttm): —
EV / EBITDA: -1.76
EPS (ttm): -1.65
EPS (forward): —
Beta (5y monthly): 1.22
Dividend yield: 0.00%
Payout ratio: 0.00%
Shares outstanding: 13.51M
Float: 7.18M
Short % of float: 1.59%
Short ratio (days): 4.95
Held by insiders: 13.55%
Held by institutions: 37.44%
Avg volume (3m): 61.99K
50-day average: 4.52
200-day average: 5.57
52-week change: +12.20%
S&P 500 52-week: +17.03%

Technicals (daily)

RSI (14): oversold 27.8
vs 50-day SMA: −36.24%
vs 200-day SMA: −48.92%
50 / 200-day trend: ▼ 50 below 200
MACD vs signal: ▼ below
ATR (14) % of price: 12.68%
Realised vol (20d, ann.): 107.5%
From 52-week high: −85.97%
From 52-week low: +295.83%

ANR

Analyst Consensus

3 analysts

Consensus

—

Mean target

16.33

+474.11% implied

Low 9.00Median 19.00High 21.00

Recommendation trend

Now2 / 0 / 0
1m ago2 / 0 / 0

Buy / hold / sell counts

DES

About Edesa Biotech, Inc.

Yahoo Finance profile

Edesa Biotech, Inc., a clinical-stage biopharmaceutical company, engages in the research and development, manufacture, and commercialization of pharmaceutical products for inflammatory and immune-related diseases. It develops EB05, a monoclonal antibody, which is in Phase 3 clinical study for the treatment of acute respiratory distress syndrome; and EB01, a topical vanishing cream containing non-steroidal anti-inflammatory compound that has completed Phase 3 clinical study to treat chronic allergic contact dermatitis. The company develops EB07, a monoclonal antibody, which is in a Phase 2 clinical study for the treatment of pulmonary fibrosis; and EB06, a human monoclonal antibody candidate that binds to chemokine ligand 10 (CXCL10) and inhibits the interaction of CXCL10 with its receptors, CXCR3A, and CXCR3B. It has a collaboration agreement with NovImmune SA to develop monoclonal antibodies targeting products containing toll-like receptor 4 and CXCL10 for therapeutic, prophylactic, and diagnostic applications in humans and animals; and Yissum Research Development Company for the development of products for therapeutic, prophylactic, and diagnostic uses in topical dermal and anorectal applications, as well as for the use in dermatologic and gastrointestinal conditions. The company was founded in 2015 and is headquartered in Markham, Canada.

Sector: Healthcare
Industry: Biotechnology
Employees: 17
Headquarters: Markham, ON, Canada
Website: edesabiotech.com
Officers: Dr. Pardeep Nijhawan FRCPC, M.D. CEO, Company Secretary & Director

SEAS

Seasonality · EDSA

2010–2026 · monthly returns

Strongest month Aug +9.47%Weakest month Apr −7.97%Averages use completed years only. Past seasonality doesn't predict future returns.

Year	Jan	Feb	Mar	Apr	May	Jun	Jul	Aug	Sep	Oct	Nov	Dec	Year
2026	-17.6	88.0	137.7	249.5	-60.5	12.6	-37.1	-7.2	-11.2	-32.4			+100.4%
2025	13.7	14.7	11.4	-4.5	-15.9	3.6	10.8	3.1	6.5	-24.7	-5.9	-18.9	−15.5%
2024	-2.6	3.8	-9.3	6.0	-2.5	-1.2	23.8	-15.1	-1.1	-25.8	-26.1	-31.1	−63.2%
2023	-30.6	-4.7	-36.4	23.1	-18.8	-11.0	1.2	3.7	-25.9	-27.0	2.5	38.5	−69.8%
2022	-26.5	-10.4	-19.9	-25.3	-7.2	-21.8	11.8	4.4	-51.1	12.0	-10.7	134.8	−61.6%
2021	35.5	-4.2	-2.2	2.8	13.0	-15.8	-5.5	17.6	25.7	11.4	-23.1	-10.9	+32.5%
2020	-23.2	-16.5	-18.6	14.0	25.8	59.9	39.5	36.2	-13.5	-25.2	-13.7	-18.4	+3.7%
2019	45.1	-11.4	-6.8	-3.7	85.7	-39.8	-30.7	-21.7	63.1	-10.8	-10.1	-18.0	−24.9%
2018	3.7	-6.0	3.8	-17.1	-62.2	0.0	-14.4	-10.4	0.7	-23.7	5.7	-18.7	−84.0%
2017	-5.9	-19.9	6.5	-17.8	-8.2	-0.8	12.3	-14.6	-3.4	2.7	-4.3	-27.0	−60.1%
2016	-1.4	4.5	-27.5	-25.8	-13.9	23.2	-18.3	-13.1	-11.4	-12.9	-5.3	2.5	−68.7%
2015	-6.9	-11.1	-8.3	-18.2	-1.4	-14.1	1.6	38.7	-25.6	24.4	7.5	-24.2	−44.1%
2014	-13.6	-2.6	16.9	-39.3	-5.7	-10.1	5.6	69.1	-25.2	4.2	4.8	-10.8	−34.1%
2013	31.0	63.2	1.6	-1.6	16.1	2.8	41.9	33.3	-2.1	35.0	-7.6	2.9	+506.9%
2012	17.9	8.7	-20.0	2.5	-39.0	12.0	39.3	-12.8	-17.6	-3.6	-22.2	38.1	−25.6%
2011	-25.9	0.0	-10.4	-14.7	-21.0	-15.6	9.3	-5.1	-26.8	-2.4	17.5	-17.0	−72.7%
2010							0.0	38.1	62.1	80.9	23.5	36.2	+581.0%

INSD

Insider Activity · EDSA

Market-wide insider buying →Congress trades →SEC Form 4 filings via Yahoo Finance

Buys, 6 months

0 shares

Sells, 6 months

— shares

Net shares

Net change in insider shares

—

Date	Insider	Transaction	Shares	Value
Oct 4, 2026	Nijhawan PardeepChief Executive Officer	Stock Award(Grant) at price 0.00 per share.	6.9K	—
Aug 31, 2026	Nijhawan PardeepChief Executive Officer	Stock Award(Grant) at price 0.00 per share.	5.7K	—
Aug 2, 2026	Nijhawan PardeepChief Executive Officer	Stock Award(Grant) at price 0.00 per share.	5.3K	—
Jul 1, 2026	Nijhawan PardeepChief Executive Officer	Stock Award(Grant) at price 0.00 per share.	3.4K	—
Jun 15, 2026	Nijhawan PardeepChief Executive Officer	Stock Award(Grant) at price 5.21 per share.	153.6K	$800.00K
May 31, 2026	Nijhawan PardeepChief Executive Officer	Stock Award(Grant) at price 0.00 per share.	1.7K	—
May 26, 2026	Macdonald Sean ArthurDirector	Stock Award(Grant) at price 0.00 per share.	19K	—
May 26, 2026	Brooks Michael J Ph.D.President	Stock Award(Grant) at price 0.00 per share.	64.6K	—
May 26, 2026	Sistilli CarloDirector	Stock Award(Grant) at price 0.00 per share.	19K	—
May 26, 2026	Marshall PatrickDirector	Stock Award(Grant) at price 0.00 per share.	19K	—
May 26, 2026	Chypyha JoanDirector	Stock Award(Grant) at price 0.00 per share.	19K	—
May 26, 2026	Liu Da DavidDirector	Stock Award(Grant) at price 0.00 per share.	19K	—
May 26, 2026	Weiler Peter JohnChief Financial Officer	Stock Award(Grant) at price 0.00 per share.	64.6K	—
May 26, 2026	Olson Charles VDirector	Stock Award(Grant) at price 0.00 per share.	19K	—
May 26, 2026	Nijhawan PardeepChief Executive Officer	Stock Award(Grant) at price 0.00 per share.	96.9K	—
Apr 30, 2026	Nijhawan PardeepChief Executive Officer	Stock Award(Grant) at price 0.00 per share.	1.2K	—
Mar 31, 2026	Nijhawan PardeepChief Executive Officer	Stock Award(Grant) at price 0.00 per share.	2.6K	—
Mar 9, 2026	Nijhawan PardeepChief Executive Officer	Purchase at price 6.60 per share.	1K	$6.60K
Mar 4, 2026	Nijhawan PardeepChief Executive Officer	Purchase at price 3.90 per share.	10K	$39.00K
Mar 3, 2026	Nijhawan PardeepChief Executive Officer	Purchase at price 4.26 per share.	10K	$42.56K

EDSA

Price Chart

Keyboard shortcuts & functions

Anywhere

Command line

Charts (click the chart first)

Function codes

EDSA

Price Chart

Key Statistics

Performance

Valuation & ownership

Technicals (daily)

Analyst Consensus

About Edesa Biotech, Inc.

Seasonality · EDSA

Insider Activity · EDSA

Congress Trades · EDSA

Investors Holding EDSA

Investors Holding EDSA

Congress Trades · EDSA

Insider Activity · EDSA

Seasonality · EDSA

Key Statistics

Performance

Valuation & ownership

Technicals (daily)

Analyst Consensus

About Edesa Biotech, Inc.

Financial Snapshot

Earnings & Dividends

News